文献速递消化道肿瘤与早癌

RNA结合蛋白RALY通过介导miRNA加工重编程结直肠癌线粒体代谢

RNA-binding protein RALY reprogrammes mitochondrial metabolism via mediating miRNA processing in colorectal cancer.
PubMed 文献 · Gut · 2020-11-20

该研究分析结直肠肿瘤进展中的基因特征,利用细胞系、人源异种移植小鼠模型和肿瘤类器官模型,发现RNA结合蛋白RALY在Drosha复合物中促进特定miRNA(miR-483、miR-676、miR-877)的转录后加工,下调代谢相关基因(ATP5I、ATP5G1、ATP5G3、CYC1)表达,重编程线粒体代谢;TCGA分析显示RALY升高与低表达线粒体相关基因的CRC患者预后不良相关;敲低RALY抑制体内和类器官中肿瘤生长与进展。

要点

  • RALY在Drosha复合物中促进miR-483、miR-676、miR-877加工,下调ATP5I、ATP5G1、ATP5G3和CYC1表达。
  • TCGA分析显示RALY升高与低表达线粒体相关基因的CRC患者预后不良相关。
  • 敲低RALY抑制体内和类器官模型中结直肠肿瘤生长与进展。

核心结论

  • RALY通过介导特定miRNA加工重编程线粒体代谢,在结直肠癌进展中起关键代谢调控作用,可能成为治疗靶点。

研究设计与样本

  • 分析结直肠肿瘤进展中的基因特征改变,并使用分子与代谢实验研究CRC细胞系、人源异种移植小鼠模型和肿瘤类器官模型。

主要发现

  • RALY(hnRNPCL2)与结直肠肿瘤侵袭性高度相关,作为Drosha复合物关键调控组分促进miR-483、miR-676和miR-877的转录后加工。
  • 这些miRNA系统性下调代谢相关基因ATP5I、ATP5G1、ATP5G3和CYC1表达,重编程癌细胞线粒体代谢。
  • TCGA分析显示RALY水平升高与低表达线粒体相关基因的CRC患者预后不良相关。
  • 在活性氧应激下,m6A开关促进这些miRNA的诱导加工;抑制m6A甲基化消除RALY对pri-miRNA末端环的识别。
  • 敲低RALY抑制体内和类器官模型中结直肠肿瘤生长与进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Dysregulated cellular metabolism is a distinct hallmark of human colorectal cancer (CRC). However, metabolic programme rewiring during tumour progression has yet to be fully understood. DESIGN: We analysed altered gene signatures during colorectal tumour progression, and used a complex of molecular and metabolic assays to study the regulation of metabolism in CRC cell lines, human patient-derived xenograft mouse models and tumour organoid models. RESULTS: We identified a novel RNA-binding protein, RALY (also known as hnRNPCL2), that is highly associated with colorectal tumour aggressiveness. RALY acts as a key regulatory component in the Drosha complex, and promotes the post-transcriptional processing of a specific subset of miRNAs (miR-483, miR-676 and miR-877). These miRNAs systematically downregulate the expression of the metabolism-associated genes (ATP5I, ATP5G1, ATP5G3 and CYC1) and thereby reprogramme mitochondrial metabolism in the cancer cell. Analysis of The Cancer Genome Atlas (TCGA) reveals that increased levels of RALY are associated with poor prognosis in the patients with CRC expressing low levels of mitochondrion-associated genes. Mechanistically, induced processing of these miRNAs is facilitated by their N6-methyladenosine switch under reactive oxygen species (ROS) stress. Inhibition of the m6A methylation abolishes the RALY recognition of the terminal loop of the pri-miRNAs. Knockdown of RALY inhibits colorectal tumour growth and progression in vivo and in organoid models. CONCLUSIONS: Collectively, our results reveal a critical metabolism-centric role of RALY in tumour progression, which may lead to cancer therapeutics targeting RALY for treating CRC.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Sun L, Wan A, Zhou Z, et al. RNA-binding protein RALY reprogrammes mitochondrial metabolism via mediating miRNA processing in colorectal cancer. Gut. 2020. PMID: 33219048. doi:10.1136/gutjnl-2020-320652

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。